Clinical efficacy and safety of oral terbinafine in fungal mycetoma

International Journal of Dermatology

Volumn 45, Issue 2, 2006, Pages 154-157

  N'Diaye, Bassirou ^a,b   Dieng, Mame T ^a,b   Perez, Antonio ^a,b   Stockmeyer, Marlies ^a,b   Bakshi, Rajesh ^a,b  

^a Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TERBINAFINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUMYCETOMA; FEMALE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LEUKOPENIA; MALE; NEUTROPENIA; OPEN STUDY; PHYSICAL EXAMINATION; SYMPTOM; TREATMENT OUTCOME; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; FEMALE; HUMANS; MADURELLA; MADUROMYCOSIS; MALE; NAPHTHALENES; TREATMENT OUTCOME;

EID: 33645985170     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02392.x     Document Type: Article

References (12)

1. Welsh O, Vera-Cabrera L, Salinas-Carmona M. Mycetoma. http://www.emedicine.com.
2. Balfour JA, Faulds D. Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-284.
3. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997; 8: 275-287.
4. Ryder NS. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126: 2-7.
5. McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol 1998; 36: 243-246.
6. K Lakhdar, et al. Personal communication.
7. Engelkens HJ, Naafs B, Mycetoma. Br J Dermatol 1994; 131: 722-737.
8. Destombe P. Histopathologie des mycétomes. Ann Soc Belg Med 1972; 52: 261-276.
9. Fahal AH, Hassan MA. Mycetoma. Br J Surg 1992; 79: 1138-1141.
10. Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol 1994; 31: S91-S102.
11. Chapman P, Pappas P, Kauffman C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg/day) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 2004; 47: 62-68.
12. Esterre P, Inzan C, Ratsioharana M, et al. A multicentre trial of terbinafine in patients with chromoblastomycosis: Effect on clinical and biological criteria. J Dermatol Treat 1998; 9: S29-S34.